Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Innate Pharma

Nasdaq:IPHA
Snowflake Description

Excellent balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
IPHA
Nasdaq
€377M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Innate Pharma S.A., a clinical-stage biotechnology company, discovers and develops therapeutic antibodies for the treatment of cancer in France and internationally. The last earnings update was 18 days ago. More info.


Add to Portfolio Compare Print
  • Innate Pharma has significant price volatility in the past 3 months.
IPHA Share Price and Events
7 Day Returns
33.2%
NasdaqGS:IPHA
5.2%
US Biotechs
10.5%
US Market
1 Year Returns
-
NasdaqGS:IPHA
0%
US Biotechs
-11.5%
US Market
IPHA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Innate Pharma (IPHA) 33.2% -33.9% -19.2% - - -
US Biotechs 5.2% -6.5% -8.7% 0% 6.2% -10.4%
US Market 10.5% -15.4% -21.4% -11.5% 5.4% 18.1%
1 Year Return vs Industry and Market
  • No trading data on IPHA.
  • No trading data on IPHA.
Price Volatility
IPHA
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Innate Pharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Innate Pharma. This is due to cash flow or dividend data being unavailable. The share price is $5.25.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Innate Pharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Innate Pharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:IPHA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in EUR €-0.31
ENXTPA:IPH Share Price ** ENXTPA (2020-03-27) in EUR €4.78
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.4x
United States of America Market PE Ratio Median Figure of 2,939 Publicly-Listed Companies 12.96x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Innate Pharma.

NasdaqGS:IPHA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTPA:IPH Share Price ÷ EPS (both in EUR)

= 4.78 ÷ -0.31

-15.4x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Innate Pharma is loss making, we can't compare its value to the US Biotechs industry average.
  • Innate Pharma is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Innate Pharma's expected growth come at a high price?
Raw Data
NasdaqGS:IPHA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -15.4x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
-1.6%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.96x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Innate Pharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Innate Pharma's assets?
Raw Data
NasdaqGS:IPHA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in EUR €3.11
ENXTPA:IPH Share Price * ENXTPA (2020-03-27) in EUR €4.78
United States of America Biotechs Industry PB Ratio Median Figure of 429 Publicly-Listed Biotechs Companies 2.53x
United States of America Market PB Ratio Median Figure of 5,148 Publicly-Listed Companies 1.26x
NasdaqGS:IPHA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTPA:IPH Share Price ÷ Book Value per Share (both in EUR)

= 4.78 ÷ 3.11

1.53x

* Primary Listing of Innate Pharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Innate Pharma is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Innate Pharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Innate Pharma has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Innate Pharma expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-1.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Innate Pharma expected to grow at an attractive rate?
  • Unable to compare Innate Pharma's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Innate Pharma's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Innate Pharma's revenues are expected to decrease over the next 1-3 years, this is below the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:IPHA Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:IPHA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts -1.6%
NasdaqGS:IPHA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts -2.6%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:IPHA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:IPHA Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 85 -1 -27 2
2023-12-31 85 -9 -19 2
2022-12-31 94 -32 -31 3
2021-12-31 105 -19 -24 6
2020-12-31 119 57 -48 6
2020-03-28
NasdaqGS:IPHA Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-12-31 86 35 -21
2019-09-30 108 48 5
2019-06-30 130 61 31
2019-03-31 112 14 17
2018-12-31 94 -33 3
2018-09-30 70 -46 -18
2018-06-30 46 -59 -40
2018-03-31 45 -53 -44
2017-12-31 44 -48 -48
2017-09-30 55 -43 -28
2017-06-30 66 -38 -8
2017-03-31 66 -37 3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Innate Pharma is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Innate Pharma's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:IPHA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Innate Pharma Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:IPHA Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -0.18 -0.12 -0.24 2.00
2023-12-31 -0.08 -0.02 -0.13 2.00
2022-12-31 -0.01 0.21 -0.22 2.00
2021-12-31 -0.40 -0.23 -0.57 3.00
2020-12-31 -0.05 0.69 -0.46 4.00
2020-03-28
NasdaqGS:IPHA Past Financials Data
Date (Data in EUR Millions) EPS *
2019-12-31 -0.31
2019-09-30 0.07
2019-06-30 0.51
2019-03-31 0.29
2018-12-31 0.05
2018-09-30 -0.31
2018-06-30 -0.71
2018-03-31 -0.80
2017-12-31 -0.89
2017-09-30 -0.52
2017-06-30 -0.14
2017-03-31 0.05

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Innate Pharma will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Innate Pharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Innate Pharma has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Innate Pharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Innate Pharma's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Innate Pharma does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Innate Pharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Innate Pharma's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Innate Pharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Innate Pharma Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:IPHA Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 85.81 -20.76 25.80
2019-09-30 108.30 4.79 23.83
2019-06-30 130.11 31.41 21.86
2019-03-31 112.03 17.23 20.00
2018-12-31 93.95 3.05 18.14
2018-09-30 69.52 -18.01 16.41
2018-06-30 45.76 -40.14 14.67
2018-03-31 44.89 -44.26 15.84
2017-12-31 44.03 -48.39 17.02
2017-09-30 55.17 -27.97 15.56
2017-06-30 66.31 -7.55 14.11
2017-03-31 66.02 2.55 11.81
2016-12-31 65.72 12.64 9.52
2016-09-30 53.45 5.39 8.07
2016-06-30 41.19 -1.85 6.62
2016-03-31 33.16 -4.28 6.31
2015-12-31 25.14 -6.71 6.01
2015-09-30 16.63 -12.67 4.96
2015-06-30 8.13 -18.63 3.90
2015-03-31 7.87 -19.14 4.41
2014-12-31 7.62 -19.65 4.92
2014-09-30 10.72 -14.63 6.41
2014-06-30 13.81 -9.61 7.91
2014-03-31 15.23 -6.25 7.73
2013-12-31 16.65 -2.89 7.55
2013-09-30 15.10 -3.20 7.13
2013-06-30 13.54 -3.50 6.71
2013-03-31 13.91 -3.35 6.75

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Innate Pharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Innate Pharma has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Innate Pharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Innate Pharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Innate Pharma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Innate Pharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Innate Pharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Innate Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Innate Pharma's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Innate Pharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 14.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Innate Pharma Company Filings, last reported 2 months ago.

NasdaqGS:IPHA Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 217.42 18.72 218.87
2019-09-30 217.42 18.72 218.87
2019-06-30 181.27 2.32 164.95
2019-03-31 181.27 2.32 164.95
2018-12-31 167.24 2.43 167.53
2018-09-30 167.24 2.43 167.53
2018-06-30 87.17 0.98 96.88
2018-03-31 87.17 0.98 96.88
2017-12-31 85.96 2.85 116.11
2017-09-30 85.96 2.85 116.11
2017-06-30 68.91 1.20 171.48
2017-03-31 68.91 1.20 171.48
2016-12-31 86.17 1.43 197.69
2016-09-30 86.17 1.43 197.69
2016-06-30 69.20 1.50 203.93
2016-03-31 69.20 1.50 203.93
2015-12-31 72.07 1.50 235.91
2015-09-30 72.07 1.50 235.91
2015-06-30 69.18 1.50 278.93
2015-03-31 69.18 1.50 278.93
2014-12-31 74.63 1.50 69.24
2014-09-30 74.63 1.50 69.24
2014-06-30 85.02 1.50 78.91
2014-03-31 85.02 1.50 78.91
2013-12-31 40.29 1.63 41.35
2013-09-30 40.29 1.63 41.35
2013-06-30 21.48 0.62 24.74
2013-03-31 21.48 0.62 24.74
  • Innate Pharma's level of debt (7.3%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (1.7% vs 7.3% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Innate Pharma has sufficient cash runway for more than 3 years based on current free cash flow.
  • Innate Pharma has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 29.8% each year.
X
Financial health checks
We assess Innate Pharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Innate Pharma has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Innate Pharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Innate Pharma dividends. Estimated to be 0% next year.
If you bought $2,000 of Innate Pharma shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Innate Pharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Innate Pharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:IPHA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1949 Stocks 3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:IPHA Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2020-03-28

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Innate Pharma has not reported any payouts.
  • Unable to verify if Innate Pharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Innate Pharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Innate Pharma has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Innate Pharma's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Innate Pharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Innate Pharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Innate Pharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Innate Pharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mondher Mahjoubi
COMPENSATION €1,322,183
AGE 61
TENURE AS CEO 3.3 years
CEO Bio

Dr. Mondher Mahjoubi, M.D., has been the Chairman of Executive Board and Chief Executive Officer of Innate Pharma S.A. since December 30, 2016. Dr. Mahjoubi has more than 20 years of experience working in clinical development, marketing and strategy in Europe and the USA for leading pharmaceutical companies in the field of oncology such as Aventis, Sanofi, Roche-Genentech and AstraZeneca. Dr. Mahjoubi served as Senior Vice President, Therapeutic Area Head of Oncology, Global Product and Portfolio Strategy at AstraZeneca PLC until January 2017. He is instrumental in driving the oncology strategy at AstraZeneca and beforehand at Genentech. Dr. Mahjoubi is a medical oncologist trained at Institut Gustave Roussy (Paris-Villejuif). Dr. Mahjoubi holds a MD from the University of Tunis and certifications in Medical Oncology from the University of Tunis and University of Paris Sud and in Clinical Research and Methodology from the University of Lariboisiere-Saint Louis. He is trained as a medical oncologist and is a member of the American Society of Clinical Oncology and European Society of Medical Oncology.

CEO Compensation
  • Mondher's compensation has increased whilst company is loss making.
  • Mondher's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Innate Pharma management team in years:

4
Average Tenure
55
Average Age
  • The tenure for the Innate Pharma management team is about average.
Management Team

Hervé Brailly

TITLE
Co-Founder & Chairman of Supervisory Board
COMPENSATION
€150K
AGE
58
TENURE
21.2 yrs

Mondher Mahjoubi

TITLE
Chairman of Executive Board & CEO
COMPENSATION
€1M
AGE
61
TENURE
3.3 yrs

Yannis Morel

TITLE
Executive VP of Product Portfolio Strategy & Business Development and Member of Executive Board
COMPENSATION
€552K
AGE
46
TENURE
4.8 yrs

François Romagné

TITLE
AGE
55

Eric Vivier

TITLE
Founder
AGE
55

Marc Bonneville

TITLE
AGE
58

Jean Fournié

TITLE

Alessandro Moretta

TITLE

Laure-Hélène Mercier

TITLE
Executive VP
AGE
41
TENURE
3.3 yrs

Danielle Spangler

TITLE
Head of Investor Relations
Board of Directors Tenure

Average tenure and age of the Innate Pharma board of directors in years:

3
Average Tenure
58
Average Age
  • The tenure for the Innate Pharma board of directors is about average.
Board of Directors

Hervé Brailly

TITLE
Co-Founder & Chairman of Supervisory Board
COMPENSATION
€150K
AGE
58
TENURE
3.3 yrs

Irina Staatz-Granzer

TITLE
Vice Chairman of Supervisory Board
COMPENSATION
€29K
AGE
59

Patrick Langlois

TITLE
Member of Supervisory Board
COMPENSATION
€44K
AGE
74
TENURE
9.8 yrs

Véronique Chabernaud

TITLE
Member of Supervisory Board
COMPENSATION
€29K
AGE
58
TENURE
4.9 yrs

Miriam Merad

TITLE
Chairman of Strategic Advisory Board

Gilles Brisson

TITLE
Member of Supervisory Board
COMPENSATION
€44K
AGE
67
TENURE
12.7 yrs

Maïlys Ferrere

TITLE
Member of Supervisory Board
AGE
57
TENURE
2.8 yrs

Jean-Yves Blay

TITLE
Member of Supervisory Board
COMPENSATION
€31K
AGE
57
TENURE
2.3 yrs

Marcus Schindler

TITLE
Member of Supervisory Board
AGE
53
TENURE
2 yrs

Sebastian Amigorena

TITLE
Strategic Advisory Board Member
TENURE
1.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Innate Pharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Innate Pharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Innate Pharma S.A., a clinical-stage biotechnology company, discovers and develops therapeutic antibodies for the treatment of cancer in France and internationally. The company offers IPH4102, an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is in Phase II clinical trial for cutaneous T-cell lymphomas; Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat various cancer indications and tumors; and IPH5401, a therapeutic antibody that binds and blocks C5a receptors expressed on subsets of myeloid-derived suppressor cells and neutrophils. It also provides IPH5201, an anti-CD39 antibody and IPH5301, an anti-CD73 antibody, which is in pre-clinical stage for the treatment of immuno-oncology. In addition, the company offers IPH61, a bispecific NK cell engager that is used to create novel molecular formats to kill tumor cells through NKp46. Further, it provides Lumoxiti, a commercial-stage oncology product for treating hairy cell leukemia. Innate Pharma S.A. has licensing agreements with AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S, and Sanofi; and a clinical trial collaboration with MedImmune. The company was founded in 1999 and is headquartered in Marseille, France.

Details
Name: Innate Pharma S.A.
IPHA
Exchange: NasdaqGS
Founded: 1999
€417,881,311
78,879,689
Website: http://www.innate-pharma.com
Address: Innate Pharma S.A.
117 Avenue de Luminy,
BP 30191,
Marseille,
Provence-Alpes-Côte d'Azur, 13009,
France
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTPA IPH Category O Ordinary Shares Euronext Paris FR EUR 01. Nov 2006
OTCPK IPHY.F Category O Ordinary Shares Pink Sheets LLC US USD 01. Nov 2006
DB IDD Category O Ordinary Shares Deutsche Boerse AG DE EUR 01. Nov 2006
LSE 0EVI Category O Ordinary Shares London Stock Exchange GB EUR 01. Nov 2006
SWX IPH Category O Ordinary Shares SIX Swiss Exchange CH CHF 01. Nov 2006
BATS-CHIXE IPHP Category O Ordinary Shares BATS 'Chi-X Europe' GB EUR 01. Nov 2006
NasdaqGS IPHA SPON ADS EACH REP 1 ORD SHS Nasdaq Global Select US USD 18. Oct 2019
NasdaqGM IPHA UNSP ADS EACH REPR 1 ORD SHS Nasdaq Global Market US USD 20. Oct 2015
MUN IDDB UNSP ADS EACH REPR 1 ORD SHS Boerse Muenchen DE EUR 20. Oct 2015
MUN IDDA SPON ADS EACH REP 1 ORD SHS Boerse Muenchen DE EUR 18. Oct 2019
Number of employees
Current staff
Staff numbers
227
Innate Pharma employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 03:46
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/11
Last earnings filing: 2020/03/10
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.